Global (United States, European Union and China) Patent Medicine

Patent Medicine Comprehensive Study by Type (Product Patents, Process Patents), Application (Adult, Children), Drug Type (Solid Drug, Semi-Solid Drug, Liquid Drug, Gas/Aerosol Drug, Others), Disease Type (Cardiovascular Disease, Respiratory Disease, Immunological Disease, Blood Disease, Gastrointestinal Disease, Ophthalmic Disease, Orthopedic Disease, Neurodegenerative Disease, Others) Players and Region - Global Market Outlook to 2026

Patent Medicine Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Patent Medicine Market Scope?
A patent drug, which is also commonly known as a nostrum (our remedy), is basically a commercial product that is being developed for the very first time for a specific disease condition. It will initially be sold under a brand name under which the doctor can prescribe the drug for use by patients. Patent medicine is a concept that means that only the pharmaceutical company that owns the patent can manufacture it and make a profit from it. In most cases, a drug patent is granted to pharmaceutical companies for 20 years. In addition, the patent term for a drug sometimes has a different lifespan in years, depending on its usefulness and the country in which the patent was filed for approval. The period of validity of a patent drug is usually seven to twelve years, as a company applies for a patent prior to clinical studies to assess drug safety. Patent drug sales in the United States became increasingly restricted in the early 20th century as the Food and Drug Administration and Federal Trade Commission rolled out more and more regulations to prevent fraud, accidental poisoning, and misleading advertising. The patent medicine market will develop in the forecast period in the coming year.

The Patent Medicine market study is being classified by Type (Product Patents and Process Patents), by Application (Adult and Children) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analysts at AMA predicts that Players from European will contribute to the maximum growth of Global Patent Medicine market throughout the predicted period.

Pfizer Inc. (United States), Otsuka Pharmaceutical Co. Ltd. (Japan), Merck & Co. (United States), Novartis (Switzerland), Sanofi SA (Germany), Bristol-Myers Squibb Co. (United States), GlaxoSmithKline (United Kingdom), Amgen Inc. (United States), Hikma Pharmaceuticals (United Kingdom), AbbVie Inc. (United States) and Cipla (India) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Sun Pharmaceutical Industries (India) and Teva Pharmaceutical (Israel).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Patent Medicine market by Type, Application and Region.

On the basis of geography, the market of Patent Medicine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

In July 2020, Pfizer Inc. had submitted a patent application for a tofacitinib oral sustained-release form that was indicated for the treatment of lupus, multiple sclerosis rheumatoid arthritis, and cancer. and In July 2020, GlaxoSmithKline Biologicals SA had patented dried saponin liposomal composition that was used in the lyophilized form for the purpose of the immunogenic vaccine composition.


Influencing Market Trend
  • Robust Use of Branded Drugs over Generic Equivalents
  • Covid-19 Has Affected the Research and Development in Some Fields of Pharmaceutical Industry

Market Drivers
  • Significant Growth for Pharmaceutical Products
  • Increasing Prevalence of Diseases across the World
  • Increasing Elderly Population
  • Above-Average Expenditure on Drugs

Opportunities
  • Surgical Pharmaceutical Industry Is Experiencing Significant Growth in Patent Filing
  • Rise in Research and Development in Masks, Infra-Red Thermometers, Diagnostic Kits, and Mechanical Ventilators

Restraints
  • High Cost of Patent Medicine

Challenges
  • Majority of the Pharmaceutical Companies Practice ‘Patent Ever-Greening’


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Providers of Patent Medicine, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • Product Patents
  • Process Patents
By Application
  • Adult
  • Children
By Drug Type
  • Solid Drug
  • Semi-Solid Drug
  • Liquid Drug
  • Gas/Aerosol Drug
  • Others

By Disease Type
  • Cardiovascular Disease
  • Respiratory Disease
  • Immunological Disease
  • Blood Disease
  • Gastrointestinal Disease
  • Ophthalmic Disease
  • Orthopedic Disease
  • Neurodegenerative Disease
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Significant Growth for Pharmaceutical Products
      • 3.2.2. Increasing Prevalence of Diseases across the World
      • 3.2.3. Increasing Elderly Population
      • 3.2.4. Above-Average Expenditure on Drugs
    • 3.3. Market Challenges
      • 3.3.1. Majority of the Pharmaceutical Companies Practice ‘Patent Ever-Greening’
    • 3.4. Market Trends
      • 3.4.1. Robust Use of Branded Drugs over Generic Equivalents
      • 3.4.2. Covid-19 Has Affected the Research and Development in Some Fields of Pharmaceutical Industry
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Patent Medicine, by Type, Application, Drug Type, Disease Type and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Patent Medicine (Value)
      • 5.2.1. Global Patent Medicine by: Type (Value)
        • 5.2.1.1. Product Patents
        • 5.2.1.2. Process Patents
      • 5.2.2. Global Patent Medicine by: Application (Value)
        • 5.2.2.1. Adult
        • 5.2.2.2. Children
      • 5.2.3. Global Patent Medicine by: Drug Type (Value)
        • 5.2.3.1. Solid Drug
        • 5.2.3.2. Semi-Solid Drug
        • 5.2.3.3. Liquid Drug
        • 5.2.3.4. Gas/Aerosol Drug
        • 5.2.3.5. Others
      • 5.2.4. Global Patent Medicine by: Disease Type (Value)
        • 5.2.4.1. Cardiovascular Disease
        • 5.2.4.2. Respiratory Disease
        • 5.2.4.3. Immunological Disease
        • 5.2.4.4. Blood Disease
        • 5.2.4.5. Gastrointestinal Disease
        • 5.2.4.6. Ophthalmic Disease
        • 5.2.4.7. Orthopedic Disease
        • 5.2.4.8. Neurodegenerative Disease
        • 5.2.4.9. Others
      • 5.2.5. Global Patent Medicine Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Patent Medicine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Otsuka Pharmaceutical Co. Ltd. (Japan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck & Co. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sanofi SA (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bristol-Myers Squibb Co. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. GlaxoSmithKline (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Amgen Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Hikma Pharmaceuticals (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AbbVie Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Cipla (India)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Patent Medicine Sale, by Type, Application, Drug Type, Disease Type and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Patent Medicine (Value)
      • 7.2.1. Global Patent Medicine by: Type (Value)
        • 7.2.1.1. Product Patents
        • 7.2.1.2. Process Patents
      • 7.2.2. Global Patent Medicine by: Application (Value)
        • 7.2.2.1. Adult
        • 7.2.2.2. Children
      • 7.2.3. Global Patent Medicine by: Drug Type (Value)
        • 7.2.3.1. Solid Drug
        • 7.2.3.2. Semi-Solid Drug
        • 7.2.3.3. Liquid Drug
        • 7.2.3.4. Gas/Aerosol Drug
        • 7.2.3.5. Others
      • 7.2.4. Global Patent Medicine by: Disease Type (Value)
        • 7.2.4.1. Cardiovascular Disease
        • 7.2.4.2. Respiratory Disease
        • 7.2.4.3. Immunological Disease
        • 7.2.4.4. Blood Disease
        • 7.2.4.5. Gastrointestinal Disease
        • 7.2.4.6. Ophthalmic Disease
        • 7.2.4.7. Orthopedic Disease
        • 7.2.4.8. Neurodegenerative Disease
        • 7.2.4.9. Others
      • 7.2.5. Global Patent Medicine Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Patent Medicine: by Type(USD Million)
  • Table 2. Patent Medicine Product Patents , by Region USD Million (2015-2020)
  • Table 3. Patent Medicine Process Patents , by Region USD Million (2015-2020)
  • Table 4. Patent Medicine: by Application(USD Million)
  • Table 5. Patent Medicine Adult , by Region USD Million (2015-2020)
  • Table 6. Patent Medicine Children , by Region USD Million (2015-2020)
  • Table 7. Patent Medicine: by Drug Type(USD Million)
  • Table 8. Patent Medicine Solid Drug , by Region USD Million (2015-2020)
  • Table 9. Patent Medicine Semi-Solid Drug , by Region USD Million (2015-2020)
  • Table 10. Patent Medicine Liquid Drug , by Region USD Million (2015-2020)
  • Table 11. Patent Medicine Gas/Aerosol Drug , by Region USD Million (2015-2020)
  • Table 12. Patent Medicine Others , by Region USD Million (2015-2020)
  • Table 13. Patent Medicine: by Disease Type(USD Million)
  • Table 14. Patent Medicine Cardiovascular Disease , by Region USD Million (2015-2020)
  • Table 15. Patent Medicine Respiratory Disease , by Region USD Million (2015-2020)
  • Table 16. Patent Medicine Immunological Disease , by Region USD Million (2015-2020)
  • Table 17. Patent Medicine Blood Disease , by Region USD Million (2015-2020)
  • Table 18. Patent Medicine Gastrointestinal Disease , by Region USD Million (2015-2020)
  • Table 19. Patent Medicine Ophthalmic Disease , by Region USD Million (2015-2020)
  • Table 20. Patent Medicine Orthopedic Disease , by Region USD Million (2015-2020)
  • Table 21. Patent Medicine Neurodegenerative Disease , by Region USD Million (2015-2020)
  • Table 22. Patent Medicine Others , by Region USD Million (2015-2020)
  • Table 23. South America Patent Medicine, by Country USD Million (2015-2020)
  • Table 24. South America Patent Medicine, by Type USD Million (2015-2020)
  • Table 25. South America Patent Medicine, by Application USD Million (2015-2020)
  • Table 26. South America Patent Medicine, by Drug Type USD Million (2015-2020)
  • Table 27. South America Patent Medicine, by Disease Type USD Million (2015-2020)
  • Table 28. Brazil Patent Medicine, by Type USD Million (2015-2020)
  • Table 29. Brazil Patent Medicine, by Application USD Million (2015-2020)
  • Table 30. Brazil Patent Medicine, by Drug Type USD Million (2015-2020)
  • Table 31. Brazil Patent Medicine, by Disease Type USD Million (2015-2020)
  • Table 32. Argentina Patent Medicine, by Type USD Million (2015-2020)
  • Table 33. Argentina Patent Medicine, by Application USD Million (2015-2020)
  • Table 34. Argentina Patent Medicine, by Drug Type USD Million (2015-2020)
  • Table 35. Argentina Patent Medicine, by Disease Type USD Million (2015-2020)
  • Table 36. Rest of South America Patent Medicine, by Type USD Million (2015-2020)
  • Table 37. Rest of South America Patent Medicine, by Application USD Million (2015-2020)
  • Table 38. Rest of South America Patent Medicine, by Drug Type USD Million (2015-2020)
  • Table 39. Rest of South America Patent Medicine, by Disease Type USD Million (2015-2020)
  • Table 40. Asia Pacific Patent Medicine, by Country USD Million (2015-2020)
  • Table 41. Asia Pacific Patent Medicine, by Type USD Million (2015-2020)
  • Table 42. Asia Pacific Patent Medicine, by Application USD Million (2015-2020)
  • Table 43. Asia Pacific Patent Medicine, by Drug Type USD Million (2015-2020)
  • Table 44. Asia Pacific Patent Medicine, by Disease Type USD Million (2015-2020)
  • Table 45. China Patent Medicine, by Type USD Million (2015-2020)
  • Table 46. China Patent Medicine, by Application USD Million (2015-2020)
  • Table 47. China Patent Medicine, by Drug Type USD Million (2015-2020)
  • Table 48. China Patent Medicine, by Disease Type USD Million (2015-2020)
  • Table 49. Japan Patent Medicine, by Type USD Million (2015-2020)
  • Table 50. Japan Patent Medicine, by Application USD Million (2015-2020)
  • Table 51. Japan Patent Medicine, by Drug Type USD Million (2015-2020)
  • Table 52. Japan Patent Medicine, by Disease Type USD Million (2015-2020)
  • Table 53. India Patent Medicine, by Type USD Million (2015-2020)
  • Table 54. India Patent Medicine, by Application USD Million (2015-2020)
  • Table 55. India Patent Medicine, by Drug Type USD Million (2015-2020)
  • Table 56. India Patent Medicine, by Disease Type USD Million (2015-2020)
  • Table 57. South Korea Patent Medicine, by Type USD Million (2015-2020)
  • Table 58. South Korea Patent Medicine, by Application USD Million (2015-2020)
  • Table 59. South Korea Patent Medicine, by Drug Type USD Million (2015-2020)
  • Table 60. South Korea Patent Medicine, by Disease Type USD Million (2015-2020)
  • Table 61. Taiwan Patent Medicine, by Type USD Million (2015-2020)
  • Table 62. Taiwan Patent Medicine, by Application USD Million (2015-2020)
  • Table 63. Taiwan Patent Medicine, by Drug Type USD Million (2015-2020)
  • Table 64. Taiwan Patent Medicine, by Disease Type USD Million (2015-2020)
  • Table 65. Australia Patent Medicine, by Type USD Million (2015-2020)
  • Table 66. Australia Patent Medicine, by Application USD Million (2015-2020)
  • Table 67. Australia Patent Medicine, by Drug Type USD Million (2015-2020)
  • Table 68. Australia Patent Medicine, by Disease Type USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Patent Medicine, by Type USD Million (2015-2020)
  • Table 70. Rest of Asia-Pacific Patent Medicine, by Application USD Million (2015-2020)
  • Table 71. Rest of Asia-Pacific Patent Medicine, by Drug Type USD Million (2015-2020)
  • Table 72. Rest of Asia-Pacific Patent Medicine, by Disease Type USD Million (2015-2020)
  • Table 73. Europe Patent Medicine, by Country USD Million (2015-2020)
  • Table 74. Europe Patent Medicine, by Type USD Million (2015-2020)
  • Table 75. Europe Patent Medicine, by Application USD Million (2015-2020)
  • Table 76. Europe Patent Medicine, by Drug Type USD Million (2015-2020)
  • Table 77. Europe Patent Medicine, by Disease Type USD Million (2015-2020)
  • Table 78. Germany Patent Medicine, by Type USD Million (2015-2020)
  • Table 79. Germany Patent Medicine, by Application USD Million (2015-2020)
  • Table 80. Germany Patent Medicine, by Drug Type USD Million (2015-2020)
  • Table 81. Germany Patent Medicine, by Disease Type USD Million (2015-2020)
  • Table 82. France Patent Medicine, by Type USD Million (2015-2020)
  • Table 83. France Patent Medicine, by Application USD Million (2015-2020)
  • Table 84. France Patent Medicine, by Drug Type USD Million (2015-2020)
  • Table 85. France Patent Medicine, by Disease Type USD Million (2015-2020)
  • Table 86. Italy Patent Medicine, by Type USD Million (2015-2020)
  • Table 87. Italy Patent Medicine, by Application USD Million (2015-2020)
  • Table 88. Italy Patent Medicine, by Drug Type USD Million (2015-2020)
  • Table 89. Italy Patent Medicine, by Disease Type USD Million (2015-2020)
  • Table 90. United Kingdom Patent Medicine, by Type USD Million (2015-2020)
  • Table 91. United Kingdom Patent Medicine, by Application USD Million (2015-2020)
  • Table 92. United Kingdom Patent Medicine, by Drug Type USD Million (2015-2020)
  • Table 93. United Kingdom Patent Medicine, by Disease Type USD Million (2015-2020)
  • Table 94. Netherlands Patent Medicine, by Type USD Million (2015-2020)
  • Table 95. Netherlands Patent Medicine, by Application USD Million (2015-2020)
  • Table 96. Netherlands Patent Medicine, by Drug Type USD Million (2015-2020)
  • Table 97. Netherlands Patent Medicine, by Disease Type USD Million (2015-2020)
  • Table 98. Rest of Europe Patent Medicine, by Type USD Million (2015-2020)
  • Table 99. Rest of Europe Patent Medicine, by Application USD Million (2015-2020)
  • Table 100. Rest of Europe Patent Medicine, by Drug Type USD Million (2015-2020)
  • Table 101. Rest of Europe Patent Medicine, by Disease Type USD Million (2015-2020)
  • Table 102. MEA Patent Medicine, by Country USD Million (2015-2020)
  • Table 103. MEA Patent Medicine, by Type USD Million (2015-2020)
  • Table 104. MEA Patent Medicine, by Application USD Million (2015-2020)
  • Table 105. MEA Patent Medicine, by Drug Type USD Million (2015-2020)
  • Table 106. MEA Patent Medicine, by Disease Type USD Million (2015-2020)
  • Table 107. Middle East Patent Medicine, by Type USD Million (2015-2020)
  • Table 108. Middle East Patent Medicine, by Application USD Million (2015-2020)
  • Table 109. Middle East Patent Medicine, by Drug Type USD Million (2015-2020)
  • Table 110. Middle East Patent Medicine, by Disease Type USD Million (2015-2020)
  • Table 111. Africa Patent Medicine, by Type USD Million (2015-2020)
  • Table 112. Africa Patent Medicine, by Application USD Million (2015-2020)
  • Table 113. Africa Patent Medicine, by Drug Type USD Million (2015-2020)
  • Table 114. Africa Patent Medicine, by Disease Type USD Million (2015-2020)
  • Table 115. North America Patent Medicine, by Country USD Million (2015-2020)
  • Table 116. North America Patent Medicine, by Type USD Million (2015-2020)
  • Table 117. North America Patent Medicine, by Application USD Million (2015-2020)
  • Table 118. North America Patent Medicine, by Drug Type USD Million (2015-2020)
  • Table 119. North America Patent Medicine, by Disease Type USD Million (2015-2020)
  • Table 120. United States Patent Medicine, by Type USD Million (2015-2020)
  • Table 121. United States Patent Medicine, by Application USD Million (2015-2020)
  • Table 122. United States Patent Medicine, by Drug Type USD Million (2015-2020)
  • Table 123. United States Patent Medicine, by Disease Type USD Million (2015-2020)
  • Table 124. Canada Patent Medicine, by Type USD Million (2015-2020)
  • Table 125. Canada Patent Medicine, by Application USD Million (2015-2020)
  • Table 126. Canada Patent Medicine, by Drug Type USD Million (2015-2020)
  • Table 127. Canada Patent Medicine, by Disease Type USD Million (2015-2020)
  • Table 128. Mexico Patent Medicine, by Type USD Million (2015-2020)
  • Table 129. Mexico Patent Medicine, by Application USD Million (2015-2020)
  • Table 130. Mexico Patent Medicine, by Drug Type USD Million (2015-2020)
  • Table 131. Mexico Patent Medicine, by Disease Type USD Million (2015-2020)
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Patent Medicine: by Type(USD Million)
  • Table 144. Patent Medicine Product Patents , by Region USD Million (2021-2026)
  • Table 145. Patent Medicine Process Patents , by Region USD Million (2021-2026)
  • Table 146. Patent Medicine: by Application(USD Million)
  • Table 147. Patent Medicine Adult , by Region USD Million (2021-2026)
  • Table 148. Patent Medicine Children , by Region USD Million (2021-2026)
  • Table 149. Patent Medicine: by Drug Type(USD Million)
  • Table 150. Patent Medicine Solid Drug , by Region USD Million (2021-2026)
  • Table 151. Patent Medicine Semi-Solid Drug , by Region USD Million (2021-2026)
  • Table 152. Patent Medicine Liquid Drug , by Region USD Million (2021-2026)
  • Table 153. Patent Medicine Gas/Aerosol Drug , by Region USD Million (2021-2026)
  • Table 154. Patent Medicine Others , by Region USD Million (2021-2026)
  • Table 155. Patent Medicine: by Disease Type(USD Million)
  • Table 156. Patent Medicine Cardiovascular Disease , by Region USD Million (2021-2026)
  • Table 157. Patent Medicine Respiratory Disease , by Region USD Million (2021-2026)
  • Table 158. Patent Medicine Immunological Disease , by Region USD Million (2021-2026)
  • Table 159. Patent Medicine Blood Disease , by Region USD Million (2021-2026)
  • Table 160. Patent Medicine Gastrointestinal Disease , by Region USD Million (2021-2026)
  • Table 161. Patent Medicine Ophthalmic Disease , by Region USD Million (2021-2026)
  • Table 162. Patent Medicine Orthopedic Disease , by Region USD Million (2021-2026)
  • Table 163. Patent Medicine Neurodegenerative Disease , by Region USD Million (2021-2026)
  • Table 164. Patent Medicine Others , by Region USD Million (2021-2026)
  • Table 165. South America Patent Medicine, by Country USD Million (2021-2026)
  • Table 166. South America Patent Medicine, by Type USD Million (2021-2026)
  • Table 167. South America Patent Medicine, by Application USD Million (2021-2026)
  • Table 168. South America Patent Medicine, by Drug Type USD Million (2021-2026)
  • Table 169. South America Patent Medicine, by Disease Type USD Million (2021-2026)
  • Table 170. Brazil Patent Medicine, by Type USD Million (2021-2026)
  • Table 171. Brazil Patent Medicine, by Application USD Million (2021-2026)
  • Table 172. Brazil Patent Medicine, by Drug Type USD Million (2021-2026)
  • Table 173. Brazil Patent Medicine, by Disease Type USD Million (2021-2026)
  • Table 174. Argentina Patent Medicine, by Type USD Million (2021-2026)
  • Table 175. Argentina Patent Medicine, by Application USD Million (2021-2026)
  • Table 176. Argentina Patent Medicine, by Drug Type USD Million (2021-2026)
  • Table 177. Argentina Patent Medicine, by Disease Type USD Million (2021-2026)
  • Table 178. Rest of South America Patent Medicine, by Type USD Million (2021-2026)
  • Table 179. Rest of South America Patent Medicine, by Application USD Million (2021-2026)
  • Table 180. Rest of South America Patent Medicine, by Drug Type USD Million (2021-2026)
  • Table 181. Rest of South America Patent Medicine, by Disease Type USD Million (2021-2026)
  • Table 182. Asia Pacific Patent Medicine, by Country USD Million (2021-2026)
  • Table 183. Asia Pacific Patent Medicine, by Type USD Million (2021-2026)
  • Table 184. Asia Pacific Patent Medicine, by Application USD Million (2021-2026)
  • Table 185. Asia Pacific Patent Medicine, by Drug Type USD Million (2021-2026)
  • Table 186. Asia Pacific Patent Medicine, by Disease Type USD Million (2021-2026)
  • Table 187. China Patent Medicine, by Type USD Million (2021-2026)
  • Table 188. China Patent Medicine, by Application USD Million (2021-2026)
  • Table 189. China Patent Medicine, by Drug Type USD Million (2021-2026)
  • Table 190. China Patent Medicine, by Disease Type USD Million (2021-2026)
  • Table 191. Japan Patent Medicine, by Type USD Million (2021-2026)
  • Table 192. Japan Patent Medicine, by Application USD Million (2021-2026)
  • Table 193. Japan Patent Medicine, by Drug Type USD Million (2021-2026)
  • Table 194. Japan Patent Medicine, by Disease Type USD Million (2021-2026)
  • Table 195. India Patent Medicine, by Type USD Million (2021-2026)
  • Table 196. India Patent Medicine, by Application USD Million (2021-2026)
  • Table 197. India Patent Medicine, by Drug Type USD Million (2021-2026)
  • Table 198. India Patent Medicine, by Disease Type USD Million (2021-2026)
  • Table 199. South Korea Patent Medicine, by Type USD Million (2021-2026)
  • Table 200. South Korea Patent Medicine, by Application USD Million (2021-2026)
  • Table 201. South Korea Patent Medicine, by Drug Type USD Million (2021-2026)
  • Table 202. South Korea Patent Medicine, by Disease Type USD Million (2021-2026)
  • Table 203. Taiwan Patent Medicine, by Type USD Million (2021-2026)
  • Table 204. Taiwan Patent Medicine, by Application USD Million (2021-2026)
  • Table 205. Taiwan Patent Medicine, by Drug Type USD Million (2021-2026)
  • Table 206. Taiwan Patent Medicine, by Disease Type USD Million (2021-2026)
  • Table 207. Australia Patent Medicine, by Type USD Million (2021-2026)
  • Table 208. Australia Patent Medicine, by Application USD Million (2021-2026)
  • Table 209. Australia Patent Medicine, by Drug Type USD Million (2021-2026)
  • Table 210. Australia Patent Medicine, by Disease Type USD Million (2021-2026)
  • Table 211. Rest of Asia-Pacific Patent Medicine, by Type USD Million (2021-2026)
  • Table 212. Rest of Asia-Pacific Patent Medicine, by Application USD Million (2021-2026)
  • Table 213. Rest of Asia-Pacific Patent Medicine, by Drug Type USD Million (2021-2026)
  • Table 214. Rest of Asia-Pacific Patent Medicine, by Disease Type USD Million (2021-2026)
  • Table 215. Europe Patent Medicine, by Country USD Million (2021-2026)
  • Table 216. Europe Patent Medicine, by Type USD Million (2021-2026)
  • Table 217. Europe Patent Medicine, by Application USD Million (2021-2026)
  • Table 218. Europe Patent Medicine, by Drug Type USD Million (2021-2026)
  • Table 219. Europe Patent Medicine, by Disease Type USD Million (2021-2026)
  • Table 220. Germany Patent Medicine, by Type USD Million (2021-2026)
  • Table 221. Germany Patent Medicine, by Application USD Million (2021-2026)
  • Table 222. Germany Patent Medicine, by Drug Type USD Million (2021-2026)
  • Table 223. Germany Patent Medicine, by Disease Type USD Million (2021-2026)
  • Table 224. France Patent Medicine, by Type USD Million (2021-2026)
  • Table 225. France Patent Medicine, by Application USD Million (2021-2026)
  • Table 226. France Patent Medicine, by Drug Type USD Million (2021-2026)
  • Table 227. France Patent Medicine, by Disease Type USD Million (2021-2026)
  • Table 228. Italy Patent Medicine, by Type USD Million (2021-2026)
  • Table 229. Italy Patent Medicine, by Application USD Million (2021-2026)
  • Table 230. Italy Patent Medicine, by Drug Type USD Million (2021-2026)
  • Table 231. Italy Patent Medicine, by Disease Type USD Million (2021-2026)
  • Table 232. United Kingdom Patent Medicine, by Type USD Million (2021-2026)
  • Table 233. United Kingdom Patent Medicine, by Application USD Million (2021-2026)
  • Table 234. United Kingdom Patent Medicine, by Drug Type USD Million (2021-2026)
  • Table 235. United Kingdom Patent Medicine, by Disease Type USD Million (2021-2026)
  • Table 236. Netherlands Patent Medicine, by Type USD Million (2021-2026)
  • Table 237. Netherlands Patent Medicine, by Application USD Million (2021-2026)
  • Table 238. Netherlands Patent Medicine, by Drug Type USD Million (2021-2026)
  • Table 239. Netherlands Patent Medicine, by Disease Type USD Million (2021-2026)
  • Table 240. Rest of Europe Patent Medicine, by Type USD Million (2021-2026)
  • Table 241. Rest of Europe Patent Medicine, by Application USD Million (2021-2026)
  • Table 242. Rest of Europe Patent Medicine, by Drug Type USD Million (2021-2026)
  • Table 243. Rest of Europe Patent Medicine, by Disease Type USD Million (2021-2026)
  • Table 244. MEA Patent Medicine, by Country USD Million (2021-2026)
  • Table 245. MEA Patent Medicine, by Type USD Million (2021-2026)
  • Table 246. MEA Patent Medicine, by Application USD Million (2021-2026)
  • Table 247. MEA Patent Medicine, by Drug Type USD Million (2021-2026)
  • Table 248. MEA Patent Medicine, by Disease Type USD Million (2021-2026)
  • Table 249. Middle East Patent Medicine, by Type USD Million (2021-2026)
  • Table 250. Middle East Patent Medicine, by Application USD Million (2021-2026)
  • Table 251. Middle East Patent Medicine, by Drug Type USD Million (2021-2026)
  • Table 252. Middle East Patent Medicine, by Disease Type USD Million (2021-2026)
  • Table 253. Africa Patent Medicine, by Type USD Million (2021-2026)
  • Table 254. Africa Patent Medicine, by Application USD Million (2021-2026)
  • Table 255. Africa Patent Medicine, by Drug Type USD Million (2021-2026)
  • Table 256. Africa Patent Medicine, by Disease Type USD Million (2021-2026)
  • Table 257. North America Patent Medicine, by Country USD Million (2021-2026)
  • Table 258. North America Patent Medicine, by Type USD Million (2021-2026)
  • Table 259. North America Patent Medicine, by Application USD Million (2021-2026)
  • Table 260. North America Patent Medicine, by Drug Type USD Million (2021-2026)
  • Table 261. North America Patent Medicine, by Disease Type USD Million (2021-2026)
  • Table 262. United States Patent Medicine, by Type USD Million (2021-2026)
  • Table 263. United States Patent Medicine, by Application USD Million (2021-2026)
  • Table 264. United States Patent Medicine, by Drug Type USD Million (2021-2026)
  • Table 265. United States Patent Medicine, by Disease Type USD Million (2021-2026)
  • Table 266. Canada Patent Medicine, by Type USD Million (2021-2026)
  • Table 267. Canada Patent Medicine, by Application USD Million (2021-2026)
  • Table 268. Canada Patent Medicine, by Drug Type USD Million (2021-2026)
  • Table 269. Canada Patent Medicine, by Disease Type USD Million (2021-2026)
  • Table 270. Mexico Patent Medicine, by Type USD Million (2021-2026)
  • Table 271. Mexico Patent Medicine, by Application USD Million (2021-2026)
  • Table 272. Mexico Patent Medicine, by Drug Type USD Million (2021-2026)
  • Table 273. Mexico Patent Medicine, by Disease Type USD Million (2021-2026)
  • Table 274. Research Programs/Design for This Report
  • Table 275. Key Data Information from Secondary Sources
  • Table 276. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Patent Medicine: by Type USD Million (2015-2020)
  • Figure 5. Global Patent Medicine: by Application USD Million (2015-2020)
  • Figure 6. Global Patent Medicine: by Drug Type USD Million (2015-2020)
  • Figure 7. Global Patent Medicine: by Disease Type USD Million (2015-2020)
  • Figure 8. South America Patent Medicine Share (%), by Country
  • Figure 9. Asia Pacific Patent Medicine Share (%), by Country
  • Figure 10. Europe Patent Medicine Share (%), by Country
  • Figure 11. MEA Patent Medicine Share (%), by Country
  • Figure 12. North America Patent Medicine Share (%), by Country
  • Figure 13. Global Patent Medicine share by Players 2020 (%)
  • Figure 14. Global Patent Medicine share by Players (Top 3) 2020(%)
  • Figure 15. Global Patent Medicine share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 19. Otsuka Pharmaceutical Co. Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 20. Otsuka Pharmaceutical Co. Ltd. (Japan) Revenue: by Geography 2020
  • Figure 21. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Merck & Co. (United States) Revenue: by Geography 2020
  • Figure 23. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. Novartis (Switzerland) Revenue: by Geography 2020
  • Figure 25. Sanofi SA (Germany) Revenue, Net Income and Gross profit
  • Figure 26. Sanofi SA (Germany) Revenue: by Geography 2020
  • Figure 27. Bristol-Myers Squibb Co. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Bristol-Myers Squibb Co. (United States) Revenue: by Geography 2020
  • Figure 29. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2020
  • Figure 31. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Amgen Inc. (United States) Revenue: by Geography 2020
  • Figure 33. Hikma Pharmaceuticals (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. Hikma Pharmaceuticals (United Kingdom) Revenue: by Geography 2020
  • Figure 35. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. AbbVie Inc. (United States) Revenue: by Geography 2020
  • Figure 37. Cipla (India) Revenue, Net Income and Gross profit
  • Figure 38. Cipla (India) Revenue: by Geography 2020
  • Figure 39. Global Patent Medicine: by Type USD Million (2021-2026)
  • Figure 40. Global Patent Medicine: by Application USD Million (2021-2026)
  • Figure 41. Global Patent Medicine: by Drug Type USD Million (2021-2026)
  • Figure 42. Global Patent Medicine: by Disease Type USD Million (2021-2026)
  • Figure 43. South America Patent Medicine Share (%), by Country
  • Figure 44. Asia Pacific Patent Medicine Share (%), by Country
  • Figure 45. Europe Patent Medicine Share (%), by Country
  • Figure 46. MEA Patent Medicine Share (%), by Country
  • Figure 47. North America Patent Medicine Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer Inc. (United States)
  • Otsuka Pharmaceutical Co. Ltd. (Japan)
  • Merck & Co. (United States)
  • Novartis (Switzerland)
  • Sanofi SA (Germany)
  • Bristol-Myers Squibb Co. (United States)
  • GlaxoSmithKline (United Kingdom)
  • Amgen Inc. (United States)
  • Hikma Pharmaceuticals (United Kingdom)
  • AbbVie Inc. (United States)
  • Cipla (India)
Additional players considered in the study are as follows:
Sun Pharmaceutical Industries (India) , Teva Pharmaceutical (Israel)
Select User Access Type

Key Highlights of Report


Mar 2021 221 Pages 58 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global (United States, European Union and China) Patent Medicine Quantitative research analysis
Global (United States, European Union and China) Patent Medicine Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Global Patent Medicine market is expected to see a growth of % during projected year 2020 to 2026.
The prominent players of Global Patent Medicine market are Pfizer Inc. (United States), Otsuka Pharmaceutical Co. Ltd. (Japan), Merck & Co. (United States), Novartis (Switzerland), Sanofi SA (Germany), Bristol-Myers Squibb Co. (United States), GlaxoSmithKline (United Kingdom), Amgen Inc. (United States), Hikma Pharmaceuticals (United Kingdom), AbbVie Inc. (United States) and Cipla (India), to name a few.
In this highly competitive & fast evolving Patent Medicine industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.

Know More About Global (United States, European Union and China) Patent Medicine Report?

Have a Query? Click Here

Other Related Reports

Over The Counter (OTC) Drugs Comprehensive Study by Type (Analgesics, Dermatology Products, Gastrointestinal Products, Vitamins, Mineral, and Supplements (VMS), Weight Loss/Dietary Products, Ophthalm...
$ 3750
Intravenous (IV) Ibuprofen Comprehensive Study by Application (Pediatrics, Adults), Indication (Pain/Inflammatory, Fever), Form (Tablet, Capsule, Suspension, Other) Players and Region - Global Market...
$ 3500
Anticholinergic Drugs Comprehensive Study by Type (Synthetic Compounds, Natural, Semi-Synthetic Compounds), Application (Overactive Bladder, Parkinson’s Disease, Chronic Obstructive Pulmonary Disease...
$ 3650
Candesartan Comprehensive Study by Application (Hypertension, Cardiovascular Risks, Chronic Kidney Diseases), Doses (4 mg, 8 mg, 16 mg, 32 mg), Distribution Channel (Hospital Pharmacies, Retail Pharm...
$ 3450
Antifibrinolytic Drugs Comprehensive Study by Drug Type (Amicar, Aminocaproic acid, Aprotinin, Cyklokapron, Fibrinogen, human, Lysteda, RiaSTAP, Tranexamic acid injection, Tranexamic acid oral, Trasy...
$ 3750
Botulism Illness Comprehensive Study by Type (Antibiotics, Antitoxins, Other), Application (Hospitals, Clinics, Other), Distribution Channel (OTC, Prescribed) Players and Region - Global Market Outlo...
$ 3500